Morgan Stanley Beam Therapeutics Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,307,156 shares of BEAM stock, worth $39.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,307,156

Previous 822,961 58.84%

Holding current value

$39.1 Million

Previous $16.1 Million 38.34%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$14.54 - $20.24 $7.04 Million - $9.8 Million	484,195 Added 58.84%	1,307,156 $22.2 Million
Q1 2025 May 15, 2025	BUY	$19.53 - $34.09 $539,848 - $942,315	27,642 Added 3.48%	822,961 $16.1 Million
Q4 2024 Feb 14, 2025	SELL	$21.55 - $30.35 $8.89 Million - $12.5 Million	-412,438 Reduced 34.15%	795,319 $19.7 Million
Q3 2024 May 14, 2025	BUY	$22.57 - $33.14 $9.12 Million - $13.4 Million	403,928 Added 50.25%	1,207,757 $29.6 Million
Q3 2024 Nov 14, 2024	BUY	$22.57 - $33.14 $9.12 Million - $13.4 Million	403,928 Added 50.25%	1,207,757 $29.6 Million
Q2 2024 May 14, 2025	BUY	$21.22 - $32.66 $180,582 - $277,936	8,510 Added 1.07%	803,829 $18.8 Million
Q2 2024 Oct 17, 2024	SELL	$21.22 - $32.66 $70.4 Million - $108 Million	-3,319,746 Reduced 80.51%	803,829 $18.8 Million
Q2 2024 Aug 14, 2024	SELL	$21.22 - $32.66 $70.4 Million - $108 Million	-3,319,746 Reduced 80.51%	803,829 $18.8 Million
Q1 2024 Oct 17, 2024	BUY	$23.46 - $45.07 $77.9 Million - $150 Million	3,319,746 Added 412.99%	4,123,575 $136 Million
Q1 2024 Aug 16, 2024	SELL	$23.46 - $45.07 $1.43 Million - $2.74 Million	-60,767 Reduced 1.45%	4,123,575 $136 Million
Q1 2024 May 15, 2024	SELL	$23.46 - $45.07 $1.43 Million - $2.74 Million	-60,767 Reduced 1.45%	4,123,575 $136 Million
Q4 2023 Aug 16, 2024	BUY	$17.69 - $30.76 $59.8 Million - $104 Million	3,380,513 Added 420.55%	4,184,342 $114 Million
Q4 2023 Feb 13, 2024	BUY	$17.69 - $30.76 $64.8 Million - $113 Million	3,662,213 Added 701.4%	4,184,342 $114 Million
Q3 2023 Nov 15, 2023	SELL	$23.01 - $32.46 $7.2 Million - $10.2 Million	-313,063 Reduced 37.48%	522,129 $12.6 Million
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $3.08 Million - $3.78 Million	105,064 Added 14.39%	835,192 $26.7 Million
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $2.44 Million - $3.95 Million	81,024 Added 12.48%	730,128 $22.4 Million
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $4.7 Million - $6.6 Million	127,984 Added 24.56%	649,104 $25.4 Million
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $3.28 Million - $5.79 Million	-82,370 Reduced 13.65%	521,120 $24.8 Million
Q2 2022 Oct 27, 2022	BUY	$29.86 - $62.36 $1.55 Million - $3.24 Million	52,024 Added 9.43%	603,490 $23.4 Million
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $1.55 Million - $3.24 Million	52,024 Added 9.43%	603,490 $23.4 Million
Q1 2022 Oct 27, 2022	SELL	$53.73 - $82.16 $2.8 Million - $4.27 Million	-52,024 Reduced 8.62%	551,466 $31.6 Million
Q1 2022 May 13, 2022	BUY	$53.73 - $82.16 $4.05 Million - $6.19 Million	75,378 Added 15.83%	551,466 $31.6 Million
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $1.19 Million - $1.73 Million	17,464 Added 3.81%	476,088 $37.9 Million
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $38.7 Million - $61.3 Million	458,624 New	458,624 $39.9 Million

Others Institutions Holding BEAM

# of Institutions

245

Shares Held

95.7M

Call Options Held

666K

Put Options Held

1.99M

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $2.1B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account